Abstract | BACKGROUND: METHODS AND RESULTS: EPS was performed 1 month after starting amiodarone, and Holter-monitoring was recorded before and 1 month after amiodarone in 188 patients with sustained VT/VF because of structural heart diseases. In spite of the judgment of EPS (n=89) or Holter (n=75), all patients continued amiodarone. Patients were followed up to 3 years and the primary endpoint was VT/VF recurrence and secondary endpoint was death by all cause. Kaplan-Meier estimated the risk of VT/VF recurrence was significantly smaller with EPS-guided amiodarone (p<0.01) but not with Holter-guided amiodarone. Multivariate Cox hazard analysis revealed that EPS-guided amiodarone was an independent factor suppressing the recurrence of VT/VF (p<0.05, 95% confidence interval =0.15 to 0.96). In the subgroup analysis, EPS-guided amiodarone was effective in patients with relatively well-preserved left ventricular ejection fraction (LVEF > or =0.30) but not in patients with lower LVEF (LVEF <0.30). CONCLUSION: EPS-guided amiodarone was useful for preventing recurrence of VT/VF in patients with a relatively well-preserved LVEF, but not always beneficial in patients with a lower LVEF.
|
Authors | Takeshi Aiba, Kenichiro Yamagata, Wataru Shimizu, Atsushi Taguchi, Kazuhiro Satomi, Takashi Noda, Hideo Okamura, Kazuhiro Suyama, Naohiko Aihara, Shiro Kamakura, Takashi Kurita |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 72
Issue 1
Pg. 88-93
(Jan 2008)
ISSN: 1346-9843 [Print] Japan |
PMID | 18159106
(Publication Type: Clinical Trial, Comparative Study, Journal Article)
|
Chemical References |
|
Topics |
- Aged
- Amiodarone
(administration & dosage)
- Death
- Electrocardiography, Ambulatory
- Electrophysiologic Techniques, Cardiac
- Female
- Heart Diseases
- Humans
- Male
- Middle Aged
- Recurrence
- Stroke Volume
- Tachycardia, Ventricular
(drug therapy)
- Treatment Outcome
|